Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250041/S001

SELUTION SLR 014 PTCA Drug-Eluting Balloon

MedAlliance, LLC · Decision date Nov 6, 2026

MEDTECHLEDGER EXPLANATIONP250041/S001

What did the FDA approve?

The FDA recorded an approval decision on 2026-11-06 for P250041/S001, a PMA supplement to the SELUTION SLR™ 014 PTCA Drug-Eluting Balloon (product code OOB, cardiovascular; applicant MedAlliance, LLC). The supplement is listed as a Normal 180 Day Track No User Fee submission with reason Postapproval Study Protocol. This action covers the postapproval study protocol, not a new approval of the underlying device system.

The recorded statement describes the SELUTION4ISR Continued Follow-up Study, which will evaluate long-term safety and effectiveness of the SELUTION SLR PTCA DEB in 418 subjects from the premarket SELUTION4ISR study, with annual follow-up through 5 years post-procedure and efforts to minimize missing long-term data. The public documentation contains no documents, so the protocol details, endpoints and any conditions of approval cannot be verified here.

Whether the follow-up study has begun, its enrollment status and any FDA-required milestones are not stated in the available data and remain unknown.

FDA approval order statement

SELUTION4ISR Continued Follow-up Study will evaluate the long-term safety and effectiveness of the SELUTION SLR PTCA DEB in 418 subjects from the premarket study (SELUTION4ISR). Subjects will be followed annually through 5 years post-procedure, and all efforts will be made to minimize the amount of missing long-term data.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
Nov 6, 2026
FDA change category
Postapproval Study Protocol

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250041/S001
Regulatory pathway
PMA supplement
Product code
OOB
Decision code
APPR
Decision date
Nov 6, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Drug-eluting percutaneous transluminal coronary angioplasty catheter.

Product code
OOB
FDA device class
3

For the original device and its historical approval scope, see PMA P250041. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250041 · Original PMA

    SELUTION SLR 014 PTCA Drug-Eluting Balloon

  2. P250041/S001 received

    Application receipt date recorded by FDA.

  3. P250041/S001 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P250041. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250041

Product / regulatory recordCompanyPathwayDecision dateSource
MedAlliance, LLCPMA approvalSep 18, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

MedAlliance, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
4 Jenner, Suite 190, Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records